Characteristics of study cohort by race
| . | All . | Black . | White . | Other/unknown . | P . |
|---|---|---|---|---|---|
| No. of patients | 645 | 373 (57.8) | 236 | 36 | |
| No. of episodes | 1049 | 651 (62.1) | 354 | 44 | |
| Sex | .36 | ||||
| Female | 457 (71) | 257 (69) | 175 (74) | 25 (69) | |
| Male | |||||
| Age at time of episode, y | 44 (34, 55) | 44 (35, 56) | 44 (33, 55) | 45 (33, 56) | .73 |
| Episode type | .07 | ||||
| De novo | 358 (34) | 205 (31) | 136 (38) | 17 (39) | |
| Relapsed | 691 (66) | 446 (69) | 218 (62) | 27 (61) | |
| Exacerbation | 201 (19) | 139 (21) | 56 (16) | 6 (14) | .07 |
| LDH >10× ULN | 74 (7) | 53 (8) | 19 (5) | 2 (5) | .24 |
| Treatment | <.0001 | ||||
| Corticosteroids alone | 435 (41) | 284 (44) | 139 (39) | 12 (27) | |
| Rituximab* | 443 (42) | 288 (44) | 132 (37) | 23 (52) | |
| Other | 171 (16) | 79 (12) | 83 (23) | 9 (20) | |
| Follow-up time, y | 2.3 (0.4, 5.5) | 2.7 (0.6, 5.9) | 2.2 (0.1, 5.6) | 1.3 (0.1, 3.5) | .02 |
| . | All . | Black . | White . | Other/unknown . | P . |
|---|---|---|---|---|---|
| No. of patients | 645 | 373 (57.8) | 236 | 36 | |
| No. of episodes | 1049 | 651 (62.1) | 354 | 44 | |
| Sex | .36 | ||||
| Female | 457 (71) | 257 (69) | 175 (74) | 25 (69) | |
| Male | |||||
| Age at time of episode, y | 44 (34, 55) | 44 (35, 56) | 44 (33, 55) | 45 (33, 56) | .73 |
| Episode type | .07 | ||||
| De novo | 358 (34) | 205 (31) | 136 (38) | 17 (39) | |
| Relapsed | 691 (66) | 446 (69) | 218 (62) | 27 (61) | |
| Exacerbation | 201 (19) | 139 (21) | 56 (16) | 6 (14) | .07 |
| LDH >10× ULN | 74 (7) | 53 (8) | 19 (5) | 2 (5) | .24 |
| Treatment | <.0001 | ||||
| Corticosteroids alone | 435 (41) | 284 (44) | 139 (39) | 12 (27) | |
| Rituximab* | 443 (42) | 288 (44) | 132 (37) | 23 (52) | |
| Other | 171 (16) | 79 (12) | 83 (23) | 9 (20) | |
| Follow-up time, y | 2.3 (0.4, 5.5) | 2.7 (0.6, 5.9) | 2.2 (0.1, 5.6) | 1.3 (0.1, 3.5) | .02 |
Data are given as n (%) or median (interquartile range). Sex and follow-up time are summarized per patient; all others are summarized per episode.
Of 443 episodes treated with rituximab, 426 (96.2%) were treated with 375 mg/m2 for 4 weekly doses and 15 (3.4%) with 375 mg/m2 for 4 doses on days 1, 4, 8, and 15; 2 (0.5%) were treated with a combination of the 2 regimens.